Apogee Technology Announces The Publication Of An Article On Intradermal Immunization In The Proceedings Of The National Academy Of Sciences

Main Category: Immune System / Vaccines
Article Date: 27 Oct 2009 - 11:00 PDT

email to a friend   printer friendly   opinions  

Apogee Technology (PINKSHEETS: ATCS), a life sciences company focused on the development of vaccine and drug delivery systems, announced publication of an article on its intradermal immunization approach in the Online Early Edition of PNAS (the Proceedings of the National Academy of Sciences of the USA). An article entitled "Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization" describes important findings on the in vivo and in vitro performance of Company's microneedle technology and demonstrates effective intradermal vaccination from an adjuvanted patch delivery system. The technology, when used as part of an intradermal delivery system for hepatitis B surface antigen, demonstrated superior activity in the appropriate animal model compared to conventional intramascular administration. It also provided significant dose sparing potential -- the property, which can be highly desirable during times of vaccine shortages, such as epidemic emergencies, and for reducing the cost of vaccine manufacturing. The manuscript, scheduled to be published this week, is coauthored by researchers from Apogee's R&D team and collaborators from three Universities in United States and Canada.

"We are honored to have this research published in the PNAS as it serves as an important validation of Apogee's approach to intradermal vaccination," says Alexander K. Andrianov, Ph.D., Apogee's Vice President of Research & Development and corresponding co-author of the paper. "Intradermal immunization using microneedles has not been fully compatible with many vaccine adjuvants including alum, the most common adjuvant used in the vaccine market globally. We believe that introduction of polyphosphazene immunoadjuvant of the present study as a biologically potent and synergistic constituent of microneedle-based intradermal vaccine delivery represents an important step forward in the advancement of our technology."

Source
About Apogee Technology, Inc.

• Additional
• References
• Citations